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Abstract
Background: IgA nephropathy (IgAN) is the most frequent glomerulonephritis in many countries including Estonia.
There is no specific treatment for IgAN but renoprotection is indicated when proteinuria is >1 g/day. We aimed to
assess the clinicopathological correlations of IgAN and to compare the follow-up outcome of the IgAN patients
receiving renoprotection with the patients with other antihypertensive regimen treatments.
Methods: A retrospective kidney biopsy cohort study was carried out in consecutive 73 IgAN cases, using the new
Oxford classification. The baseline and follow-up (FU, 4.1 years) clinical data were collected. The patients were divided
into two main study groups according to their drug-treatment: the drug-treated and untreated patients’ groups. Two
subgroups among patients receiving two different antihypertensive drugs were formed and statistically analysed:
Renin-angiotensin system (RASb, renoprotection) - and calcium-channel blockers (CCB)-receiving patients. Also, patient’
subgroups with and without the presence of clinical and morphological risk factors were used for statistical analysis.
Results: The patients’ mean age was 33.7 years (range 16–76). Proteinuria decreased at the end of FU (0.91 g/24 h to 0.
79 g/24 h). Mean arterial pressure remained at the end of FU almost at the same level. Drug treatment was prescribed to
the patients who had lower eGFR, higher proteinuria and more severe histological lesions (S1, T1/2), while the patients
with minimal clinical symptoms and the ones with near-normal kidney function remained without drug treatment. The
kidney function remained almost at the same normal level in untreated patients irrespective of the risk factors whereas in
both treated patient’ subgroups eGFR declined. The following statistically significant correlations in the IgAN cohort were
found: correlations in patients with lower kidney function (eGFR <60 ml/min/1.73 m2), higher blood pressure (p = 0.00006)
and proteinuria were found irrespectively of the fact whether the patients received (p = 0.006) or did not receive
renoprotection (p = 0.001). The biggest significant eGFR change by Wilcoxon rank sum test was found among the
patients who had clinical and morphological risk factors and received treatment. The result was confirmed by post hoc
analysis and did not depend on the presence of treatment. In the investigation of the subgroups receiving RASb we
found that the lowering of eGFR did depend on the presence of clinical and morphological risk factors.
Conclusions: Renoprotection is only effective in preventing the progression of IgAN when clinical and morphological
risk factors are modest or missing.
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Background
IgA nephropathy (IgAN) has been found to be the most
prevalent primary glomerulonephritis in many countries
where the studies of kidney biopsy material have been
historically performed [1, 2] or recently studied [3–6].
Therefore, numerous long-term outcome investigations
with clinico-morphological assessments are available
that enhance our understanding of the progression of
the disease [7, 8]. The impact of morphological lesions
on the outcomes in IgAN has been clarified in a number
of large retrospective studies that have consistently dem-
onstrated that the stage of the disease at presentation, as
indicated by the extent of interstitial fibrosis and tubular
atrophy in the biopsy, is the strongest histological predictor
of renal survival [8]. Because of an asymptomatic disease
course in many cases, the diagnosis of the IgAN is unfortu-
nately obtained late, when chronic histological lesions are
prominent and the renal function has deteriorated.
Clinically, IgAN symptoms and progression in individ-
ual patients are variable and the course of the disease is
generally benign in cases without proteinuria, hyperten-
sion or reduced glomerular filtration rate (GFR), however,
IgAN is potentially progressive to an end-stage kidney dis-
ease (ESKD). The progression of IgAN is associated with
the increase of major risk factors, such as overweight/
obesity, hypertension, proteinuria, smoking and severe
morphological lesions (interstitial fibrosis/tubular atrophy
and segmental glomerulosclerosis), which translate into a
worse final outcome [7, 9].
The new Oxford classification of IgAN based on the
MEST score (mesangial hypercellularity, endocapillary
hypercellularity, segmental glomerulosclerosis, and tubu-
lar atrophy/interstitial fibrosis) was proposed to predict
renal outcome independently from all clinical indicators
at the time of biopsy and during the follow-up [10]. Ac-
cording to these guidelines, several studies involving large
cohorts of IgAN patients have been published [11–15]
and the comparisons of different IgAN validation studies
have been presented [16].
We have recently presented the kidney biopsy epi-
demiology and the clinicopathological study based on a
retrospective analysis of biopsy-proven IgAN cohort
over an 11-year period in Estonia [17] with the aim to
investigate clinicopathological correlations by gender,
and we found that IgA nephropathy in males progresses
more rapidly compared to females. Our next question
arising from the previous study was to ascertain the ex-
tent of clinical and morphological risk factors having
importance on the progression of IgAN and the treat-
ment’s effect on IgAN progression. It is long known
that the impairment of renal function, severe protein-
uria and arterial hypertension are the strongest clinical
predictors of an unfavourable outcome in IgAN [7].
And, histologically, segmental glomerulosclerosis and
interstitial fibrosis/tubular atrophy are the most reliable
histologic prognostic markers [18].
This is widely known that almost half of IgAN cases are
asymptomatic and, for the patients with minor urinary ab-
normalities, the mainstay of treatment is a long-term and
regular follow-up to detect renal function deterioration and
hypertension [19]. Patients with IgAN especially in early
stages, often do not receive specific treatment because of
an asymptomatic course of the disease. Since there is no
specific treatment for IgAN renoprotection (treatment with
RASb) is indicated when proteinuria is >1 g/day and corti-
costeroids (CS) when estimated glomerular filtration rate
(eGFR) is > 50 ml/min [20].
The main aim of our study was to assess the signifi-
cance of both clinical and morphological prognostic risk
factors in IgA nephropathy progression comparing risk
factors in patient’ groups with different clinical syn-
dromes and evaluate clinicopathological correlations.
Another purpose of the study was to compare the
follow-up outcome of the IgAN patients receiving reno-




During the period 2001–2011 years 578 native kidney bi-
opsies were investigated at the Department of Pathology
of Tartu University Hospital. IgAN constituted 35.5% of
all primary glomerulopathies [6]. A total of 88 cases of
IgAN during 11 years were registered. According to the
recommendations of the International Consensus of IgAN
study – the Oxford’s classification of IgAN [10, 21] – 73
IgAN cases were selected for the study.
The baseline clinical data were collected within 3 months
from the kidney biopsy and at the end of the follow-up
(FU). The medical records were reviewed with the em-
phasis on presenting clinical symptoms, physical examin-
ation findings, laboratory data, therapies, and outcome.
Collection of clinical data
The following demographic data and major clinical risk
factors (overweight/obesity, hypertension, proteinuria
and smoking) were included for statistical analysis: data
on gender and age at the time of biopsy, weight (kg),
height (cm), body mass index (BMI, kg/m2), smoking
history, presenting clinical syndrome at the time of bi-
opsy, systolic and diastolic blood pressure (mmHg),
serum creatinine (S-Creat, μmol/L), serum cholesterol
(S-Chol, mmol/L), serum albumin (S-Alb, g/L). Mean ar-
terial pressure (MAP, mmHg) was defined as diastolic
pressure plus a third of the pulse pressure. Urinary pro-
tein excretion (U-prot) was expressed in grams (g) per
24 h/1.73 m2 in children and in g per 24 h in adults
(24 h urine collection or protein/creatinine ratio).
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Microhematuria was ranked at the intervals of <75, 76–
150, >150 erythrocytes/μL. Estimated glomerular filtra-
tion rate (eGFR, ml/min/1.73 m2) was calculated using
the chronic kidney disease-epidemiology (CKD-EPI) for-
mula for adults (KDIGO) and the Schwartz formula for
children [22]. For the statistical analysis, the patients’
data were examined in three groups according to eGFR
values as follows: 1) eGFR >90 ml/min, 2) eGFR 60–
89 ml/min and 3) eGFR <60 ml/min.
Treatment of IgAN patients
The treatment information included antihypertensive,
immunosuppressive, fish oil and statins medications as
well as tonsillectomy. Fish oil and the therapy with sta-
tins as well as the therapy with corticosteroids were not
consistent and they have not been analysed separately in
the current study. Patients with nephrotic syndrome
were treated temporarily at the disease presentation with
corticosteroids beside antihypertensive therapy and
therefore this subgroup was not analysed separately. The
data of antihypertensive drug treatment were detailed,
showing the number of medications and the classes of
antihypertensives: the treatment with renin-angiotensin
system blockers (RASb): angiotensin converting enzyme
inhibitors or angiotensin receptor blockers and the treat-
ment with calcium channel blockers (CCB). Treatment
with RASb was taken as renoprotection. 45.8% of the pa-
tients did not receive any antihypertensive and immuno-
suppressive drug treatment. Thus, patients were divided
into two main study groups according to their drug-
treatment: drug-treated and untreated patient’ groups.
Two subgroups among patients receiving two different
antihypertensive drugs were formed and statistically ana-
lysed: RASb-and CCB- receiving patients. Also, patient’
subgroups with and without clinical and/or morpho-
logical risk factors presence were used for statistical
analysis.
Pathomorphological data
A simplified score sheet of the Oxford classification of
IgA nephropathy study was used [10]. Each biopsy was
scored according to the Oxford Classification [10]: the
total number of glomeruli, mesangial hypercellularity,
M0/M1 (< or equivalent to >50% of glomeruli
showing >4 mesangial cells in one area); endocapillary
proliferation, E0/E1 (present/absent), segmental glo-
merulosclerosis/adhesion, S0/S1 (present/absent);
glomerular membrane duplication, necrosis, cellular/
fibrocellular crescent were categorized as present or
absent; tubular atrophy/interstitial fibrosis, T0/T1/T2.
Arteriosclerosis, A0/A1/A2, were categorized as well
according severity absent/mild (0–25%), moderate
(26–50%) or severe (>50%).
Statistical analysis
The patients’ demographics, laboratory values, clinical
and morphological measures were described, using the
means and standard deviations (SD) for continuous vari-
ables and percentages for categorical variables. Descrip-
tive statistics were used to characterize the cohort. The
means were compared by the Student’s t-test, and the
medians were compared using the Mann–Whitney U
test. The continuous variables were compared using the
Student’s t-test for independent samples, after verifying
the normality of distribution, using the Kolmogorov-
Smirnov test, or by the analysis of variance (ANOVA)
when comparing more groups. Differences of eGFR de-
crease between study groups were assessed using
Wilcoxon rank sum test for continuous variables.
The univariate and multivariate logistic regressions were
used to examine associations between independent and
dependent variables. The independent variables included:
age, gender, BMI, MAP, eGFR, proteinuria, smoking his-
tory. The Spearman Rank Order Correlations were used
to assess bivariate relationships between clinical variables
and morphological scores. All the data were collected in a
standard Excel spreadsheet and stored on a standard Excel
database. The statistical analyses were conducted using
the Statistics 12.0 statistical programme. The statistical
significance threshold of P ≤ 0.05 was adopted.
Results
Patients’ clinical features at the time of biopsy
The patients’ demographic and clinical details are shown
in Table 1. We analysed totally 73 biopsy-proven IgAN
cases where 62% of patients were males and 38%
females. The males were affected more often than the
females (males: females = 2:1). Patients’ mean age at the
kidney disease presentation, when kidney biopsy was
performed, was 33.7 years (range 16–76 years). The
mean time between the first clinical presentation and
kidney biopsy in the cohort was 2.6 years, the mean BMI
was 26.4 ± 5.2, and, 29% of all patients were smokers,
male predominance occurred (23%). At the time of bi-
opsy, a small number of patients (4%) presented with re-
current macroscopic hematuria and the main clinical
syndromes were microscopic hematuria (48%) or micro-
hematuria with proteinuria (39%). Eight patients were
lost to follow-up. For the rest of 64 patients (59% male
and 41% female), the mean follow-up was 48.9 months
and drug treatment was prescribed for 58% of patients.
The patients in the drug-treated group were significantly
older (37.5 vs 28.8, p = 0.04), more likely to be over-
weight (27.5 vs 25.2, p = 0.02), with higher serum cre-
atinine level (106.1 vs 77.2, p = 0.02) and had lower
eGFR than the patients in untreated patient’ group (76.5
vs 98.8, p = 0.01, respectively) (Table 1). Similar clinical
picture and drugs prescription was also found in the
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patient’ subgroups according to clinical syndrome
present (Table 2). Table 3 shows that RASb were pre-
scribed to the patients having better kidney function and
lower blood pressure. The lowest kidney function was
noticed in patients receiving CCBs.
Patients’ clinical characteristics after the follow-up
Patients in the drug-treated group were older (37.5 vs.
28.8, p = 0.04), more likely to be overweight (27.5 vs.
25.2, p = 0.02), with higher serum creatinine level (106.1
vs. 77.2, p = 0.02) and had lower eGFR than the un-
treated patients (76.5 vs. 98.8, p = 0.01, respectively). At
the end of the FU the presenting clinical syndromes in
all studied patients were similar to initial presenting syn-
drome but when we compared untreated and drug-
treated patients important differences were found
(Table 2). Macrohematuria (11.1%), microhematuria
(59.3%) and asymptomatic microhematuria with protein-
uria (29.6%) were the leading syndromes among
untreated patients whereas among drug treated patients
no macrohematuria was presented and less microhema-
turia was registered (34.2%) but more microhematuria
with proteinuria (50.0%) were found. Among untreated
patients no nephrotic syndrome or kidney failure devel-
oped whereas in many drug treated patients these clin-
ical syndromes presented (10.5% nephrotic syndrome,
2.6% acute kidney injury, 2.6% chronic renal failure).
eGFR decline was registered in all clinical and morpho-
logical risk factors having patient’ subgroups independ-
ent on the given treatment (Fig. 1c).
Pathomorphological features
The following pathomorphology findings for each
biopsy were registered: 73% had diffuse mesangial
hypercellularity (M1) and 32% had endocapillary
hypercellularity (E1); segmental glomerulosclerosis/ad-
hesion was found in 52% of the cases; tubular atro-
phy/interstitial fibrosis (T1) was present in a few
Table 1 Demographic and clinical characteristics in the drug-treated and untreated IgAN patients at the time of kidney biopsy and
at the end of follow-up
Clinical data At the time of biopsy At the end of follow-up
All cases All cases Drug-treated Untreated
N 73 65 38 27
Age (years) 33.7 (16–76) 33.9 (16–76) 37.5 (16–76) 28.8 (16–46)*
Duration of follow-up (months, range) 48.9 (12–144) 46.4 (12–144) 52.8 (12–135)
BMI (kg/m2) 26.4 ± 5.2 27.1 ± 4.8 27.5 ± 5.4 25.2 ± 4.7*
Smokers (%) 29 27.7 31.6 22.2
Presenting clinical syndrome:
Macroscopic hematuria (%) 4 4.6 0 11.1
Asymptomatic microhematuria (%) 48 44.6 34.2 59.3
Asymptomatic microhematuria and proteinuria (%) 39 41.5 50.0 29.6
NS (%) 7 6.2 10.5 0
Acute renal failure (%) 1 1.5 2.6 0
CKD (eGFR < 60 ml/min/1.73 m2) (%) 1 1.5 2.6 0
MAP (mmHg) 94.5 ± 16.7 95.2 ± 9.1 96.2 ± 9.9 93.9 ± 7.7
S-Creat (μmol/L) 93.4 ± 70.7 94.4 ± 74.4 106.1 ± 94.4 77.2 ± 15.0*
eGFR (mean, ml/min per 1.73 m2) 94.9 ± 30.7 85.8 ± 28.6 76.5 ± 29.1 98.8 ± 22.5**
eGFR >90 ml/min (N) 38 34 16 18
eGFR 60–89 ml/min (N) 21 18 11 7
eGFR >60 ml/min (N) 13 13 11 2
U-Prot (g/day, range) 0.91 (0–10.2) 0.79 (0–8.5) 1.0 (0–8.5) 0.5 (0–3.5)*
<1 (%) 81 79 73.7 85.2
1–3.49 (%) 11 15 13.2 14.8
>3.5 (%) 8 6 10.5 0
Microhematuria (%) 65.8 40.0 39.5 40.7
BMI body mass index, CKD chronic kidney disease, NS nephrotic syndrome, eGFR estimated glomerular filtration rate, MAP mean arterial pressure, U-Prot urinary
protein excretion
Values are expressed as mean ± standard deviation or mean, or percent
* p-value < 0.05 versus Drug-treated; ** p-value < 0.01 versus Drug-treated
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cases (10%). Arteriosclerosis (A1 and A2) was regis-
tered in 35% of cases. The lowest MEST score was
present in the patient’ group having macroscopic
hematuria with rather mild clinical picture (Table 2).
Therefore, those patients did not receive any treat-
ment. The IgAN patients with nephrotic syndrome
had the highest MEST score (Table 2), the worst clin-
ical picture and, therefore, all of them received the
continuous treatment with antihypertensives and tem-
porary treatment with corticosteroids. A higher MEST
score was also found in patients with asymptomatic
microhematuria and proteinuria whereas two thirds
(71%) of those patients received the continuous treat-
ment with antihypertensives (Table 2).
Drug treatment was prescribed to patients who had
lower eGFR, higher proteinuria and more severe histo-
logical lesions (T1, S1), while the patients with minimal
clinical symptoms and the ones with near-normal kidney
function remained without drug treatment.
Correlation analysis
Multiple statistically significant correlations were found in
the entire IgAN study group between the MEST score
components with clinical prognostic risk factors at the
time of biopsy and after the FU as shown in Table 4. After
analysing the patients in two study groups (drug-treated
and untreated), many statistically significant correlations
disappeared in the clinicopathological correlation analysis
of the drug-treated patient’ group and only a few correla-
tions remained: M correlation between U-Prot (FU); E
correlation with U-Prot (FU); S correlation with eGFR
(FU) and U-Prot as well as with U-Prot (FU); T correlation
with S-Creat and eGFR as well as with eGFR (FU). Thus,
M1, E1, S1, T1 and A2 scores were correlated with the
levels of MAP, eGFR and proteinuria, being similar to the
results published in the Oxford classification of IgAN
study [8, 17]. A higher level of arteriosclerosis score and
MEST score was noticed in those patients whose protein-
uria was higher and eGFR was lower at the end of the
Table 3 Clinical and pathomorphological IgAN progression risk factors in studied patients at the time of kidney biopsy and at the
end of follow-up in the drug-treated patient’ group
MAP (mmHg) eGFR (ml/min) U-Prot (g/day) BMI (kg/m2) S1/T1 %
At the time of kidney biopsy
All drug-treated (N = 39) 100.8 ± 13.9 85.7 ± 32.8 1.3 (0–10.2) 27.6 ± 5.4 63.2
RASb (N = 31) 102.8 ± 14.2* 82.1 ± 32.2* 1.2 (0–10.2)* 28.4 ± 5.4 61.3
CCB (N = 8) 110.5 ± 16.4 49.5 ± 20.4 3.4 (0.1–10.2) 31.0 ± 6.2 87.5
At the end of follow-up.
All drug-treated (N = 38) 96.2 ± 9.9 76.5 ± 28.7 1.0 (0–8.5) 27.9 ± 4.9
RASb (N = 30) 95.8 ± 9.6* 73.6 ± 7.4* 1.1 (0–8.5)* 28.4 ± 4.9
CCB (N = 8) 102.7 ± 15.9 44.2 ± 20.9 2.5 (0–8.5) 30.0 ± 3.3
RASb renin-angiotensin system blockers, CCB calcium channel blockers, MAP mean arterial pressure, eGFR estimated Glomerular Filtration Rate, M/F male/female,
S1 segmental sclerosis/adhesion, T1 tubular atrophy/interstitial fibrosis > 25%
Values are expressed as mean ± standard deviation or percent or range
* p-value < 0.05. The p value compares the RASb subgroups to the groups CCB at the time of kidney biopsy or at the end of follow-up, respectively
Table 2 Pathomorphological (MEST) and clinical data of IgAN patient subgroups with specific clinical syndromes
Presenting clinical syndrome
(n, %)





















Macroscopic haematuria (3, 4%,
all Untreated)
2; 67 0 2; 67 0 98.9 ± 25.6 0.4 ± 0.3 84.3 ± 10.1 109.1 ± 16.3 0.4 ± 0.3 91.7 ± 10.9
Asymptomatic microhematuria
(35, 48%)
20; 57 7; 20 12; 34 2; 6 105.3 ± 30.7 0.1 ± 0.1 90.6 ± 8.4 95.1 ± 22.5 0.3 ± 0.8 92.2 ± 6.2
• Drug-treated (13, 37%) 9; 69 0 5; 38 2; 15 102.8 ± 36.9 0.1 ± 0.1 92.4 ± 10.5 88.8 ± 23.4 0.5 ± 1.1 92.8 ± 6.6
• Untreated (22, 63% 11; 50 7; 32 7; 32 0 106.7 ± 27.1 0.1 ± 0.1 89.7 ± 7.2 98.8 ± 21.6 0.2 ± 0.4 91.7 ± 6.0
Asymptomatic microhematuria
and proteinuria (28, 39%)
24; 86 11; 39 18; 64 3; 11 89.8 ± 20.8 0.9 ± 0.6 101.1 ± 11.2 82.1 ± 29.9 1.0 ± 1.4 97.4 ± 9.9
• Drug-treated (20, 71%) 20; 100 9; 45 14; 50 2; 7 83.0 ± 18.9 1.0 ± 0.5 102.6 ± 12.5 75.1 ± 27.9 1.0 ± 1.5 97.1 ± 10.6
• Untreated (8, 29% 4; 50 2; 25 4; 50 1; 13 106.8 ± 15.3 0.8 ± 0.6 97.3 ± 6.1 99.7 ± 28.8 1.1 ± 1.2 98.1 ± 8.5
NS (5, 7%, all drug-treated) 5; 100 4; 80 5; 100 1; 20 73.9 ± 42.5 5.9 ± 2.6 100.3 ± 10.6 67.0 ± 28.3 1.1 ± 0.7 97.5 ± 11.4
NS nephrotic syndrome, eGFR estimated glomerular filtration rate, MAP mean arterial pressure, U-Prot urinary protein excretion, M mesangial hypercellularity, E
endocapillary hypercellularity, S segmental glomerulosclerosis, T tubular atrophy/interstitial fibrosis
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follow-up. In the untreated patient’ group, only one
statistically significant correlation between the pathomor-
phological and clinical risk factors was found: between ar-
teriosclerosis and microhematuria (rs = -0.4, p = 0.04).
Kidney function and risk factors of IgAN progression
Kidney function remained almost at the same normal
level in untreated patient’ group irrespective of risk fac-
tors whereas in both treated patients’ subgroups eGFR
declined (Table 3, Fig. 1a). The lowest mean eGFR at the
end of the follow-up was in the patient’ subgroup who
received CCBs and the highest proteinuria level was also
noticed among those patients (2.5 g/24 h, range 0-8.5)
comparing with other RASb treatment receiving patient’
subgroup (Table 3). The decline of mean eGFR was no-
ticed in all study groups (Fig. 1a). The changes of eGFR
in IgAN patients were found as follows: eGFR decline
was noticed in 54.8% of patients, in 12.3% of the patients
eGFR remained at the same level and in 30.2% of the pa-
tients it slightly rose. By ANOVA, the decline of eGFR
was noticed generally in all patients’ subgroups notwith-
standing which treatment they received or what kind of
risk factors, clinical or morphological, they had. The
Wilcoxon rank sum test confirmed that the lowest eGFR
and the deepest decline were noticed in patient’ sub-
groups with both clinical and morphological risk factors
and those patients received drug treatment (Fig. 1b).
Using Mann–Whitney U comparison tests we analysed
the IgAN treatment subgroups. The following statisti-
cally significant correlations in IgAN cohort were found:
in patients with lower kidney function (eGFR <60 ml/
min), higher MAP (p = 0.00006) and proteinuria was
found irrespectively of the fact whether patients received
(p = 0.006) or did not receive RASb (p = 0.001). Drug
treatment was prescribed to patients who had lower
eGFR, higher proteinuria and more severe histological
lesions (T1/S1). Thus, patients with severe clinical and
morphological symptoms were treated but patients with
minimal clinical symptoms and with near-normal kidney
function stayed without drug treatment.
According to the results of the Kolmogorov-Smirnov
test, all the patients who received RASb therapy had sig-
nificantly higher eGFR comparing with the other treat-
ment receiving patients but their eGFR remained lower
comparing with the untreated patient’ group (p < 0.005).
There was no difference in the follow-up proteinuria
level. Examining patients with corticosteroids treatment
we did not find statistically significant differences.
The dispersion analysis showed that BP affected signifi-
cantly the dispersal of eGFR (p = 0.000005), especially when
we estimated BP concurrence with smoking (p = 0.01).
After the FU eGFR was lower in both study groups and
more significantly among the patients with clinical and
morphological risk factors (ANOVA). The biggest signifi-
cant eGFR change by the Wilcoxon rank sum test was
found among the patients who had risk factors and received
treatment. The result was confirmed by a post hoc analysis
and did not depend on the presence of treatment. In the in-
vestigation of subgroup receiving RASb we found that the
lowering of eGFR did depend of the presence of clinical
and morphological risk factors. Finally, we assessed the
study subgroups separately according only to major clinical
risk factors (overweight/obesity, hypertension, smoking and
Fig. 1 eGFR decline according to treatment regimens and IgAN
progression risk factors. a. eGFR decline in the IgAN patient’ subgroup
according to treatment regimens: untreated (N= 27), all drug-treated
(N= 38) and RASb- (N= 31) and CCB-treated (N= 6). b. eGFR decline in
the IgAN patient’ subgroups according to clinical and pathomorphological
IgAN progression risk factors: without risk factors (N= 17), with clinical risk
factors (N= 45), with histological risk factors (N= 38), with clinical and
histological risk factors (N= 27). c. eGFR in the IgAN patient’ subgroups
according to risk factors and the presence of treatment. eGFR, estimated
Glomerular Filtration Rate; KBx, kidney biopsy, FU, follow-up
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proteinuria), and the following results were found: in
patients with major clinical risk factors and without drug
treatment the decline of eGFR was 13% from initial but in
those who had major clinical risk factors and received
RASb it was 10.5%. The decline of eGFR at the end of FU
was the lowest (9.4%) in patients without clinical risk
factors and who received RASb treatment (Fig. 1c). How-
ever, we did not find statistically significant reliability for
these differences. Thus, RASb are only effective in prevent-
ing of the progression when clinical and morphological risk
factors are modest or missing.
Discussion
The current investigation is another analysis of our clinico-
morphological correlation’s study [17] where we used re-
cently published a new Oxford classification of IgAN [8].
This classification is aimed to define reproducible and use-
ful kidney biopsy-based prognostic indicators [8]. We
aimed to study the significance of both morphological and
clinical risk factors in the progression of IgAN and to assess
IgAN clinicopathological correlations as well. Also we
aimed to compare the follow-up outcome of the IgAN
patients receiving renoprotection (RASb treatment) with
the patients receiving other antihypertensive regimen treat-
ments. Our IgAN patients’ cohort consisted of patients hav-
ing normal mean eGFR at the time of biopsy unlike of
other similar studies where clinico-morphological correla-
tions have recently been studied using the Oxford classifica-
tion [23]. The mean eGFR of patients by the Oxford
derivation [24], North American validation [25], and
VALIGA studies [8] was 68.4 ml/min/1.73 m2 but in our
cohort it was 94.9 ml/min/1.73 m2 meaning that we have
been biopsied patients earlier comparing with other IgAN
studies. Probably, the most interesting characteristics of our
cohort were that almost half of the patients had only micro-
scopic haematuria presenting very early or mild disease. In
some European centres including ours and also in Japan,
patients with persistent microscopic haematuria are biop-
sied and this gives diagnosis and a chronicity level as well
to clinicians for further management of patients with early
and mild disease. And, this is also a meaning of the Oxford
classification – to find out a MEST score for better manage-
ment of patients during a long-lasting disease course. How-
ever, this difference in patients’ cohorts comparing with
other IgAN studies may give other advantages like the op-
portunity to assess more closely the impact of clinical and
morphological risk factors on the decline of renal function
in patients with early or mild disease and different
treatments.
In our study, drug treatment was prescribed to the
patients who had lower eGFR, higher proteinuria and
more severe histological lesions (S1, T1/2). The decline of
eGFR was noticed in all treated or untreated study groups.
However, eGFR stayed stable in patient’ subgroups without
risk factors and without treatment as well as without risk
factors and with RASb treatment. As mentioned above,
the mean eGFR was normal in the whole IgAN cohort
and, although, it declined in the end of the follow-up, it
still stayed at a near-normal level (85.8 ml/min/1.73 m2).
IgAN patients with less clinical symptoms (lower MAP,
without proteinuria, with normal kidney function) stayed
without treatment but patients with severe clinical symp-
toms (higher MAP, microhematuria with proteinuria,
lower kidney function) and serious morphological lesions
(S1, T1/2) were treated. A similar management of IgAN
where the drug-treatment is mostly indicated for more ser-
ious cases has also been described in many other studies
[23]. The optimal approach to the treatment of IgAN is
still uncertain but renoprotection is a well-known ap-
proach in the management of various chronic kidney dis-
eases today following basic experimental [26, 27] and
clinical landmark studies [28–30]. Our study revealed that
RASb were generally effective in arresting the IgAN pro-
gression and diminishing proteinuria but RASb, as reno-
protection, were not effective in patients with clinical and
Table 4 Correlation between patomorphological (MEST) and










(N = 39) p value
M & S-Creat 0.3 0.02 - NS
M & eGFR −0.3 0.03 - NS
M & eGFR
(FU)
−0.3 0.01 - NS
M & U-Prot 0.4 0.0001 - NS
M & U-Prot
(FU)
0.3 0.04 0.3 0.04
E & MAP 0.3 NS 0.6 0.03
E & S-Creat 0.3 0.02 - NS
E & U-Prot 0.3 0.003 - NS
E & S-Chol 0.3 0.008 - NS
S & eGFR −0.3 0.02 - NS
S & eGFR
(FU)
−0.4 0.0006 −0.4 0.02
S & U-Prot 0.5 0.00004 0.5 0.0006
S & U-Prot
(FU)
0.4 0.0006 0.5 0.002
T & Age 0.3 0.03 - NS
T & S-Creat 0.4 0.002 0.6 0.0002
T & MAP
(FU)
0.3 0.03 - NS
T & eGFR −0.4 0.0009 −0.5 0.0009
T & eGFR
(FU)
−0.5 0.00004 −0.5 0.001
M mesangial hypercellularity, E endocapillary hypercellularity, S segmental
glomerulosclerosis, T tubular atrophy/interstitial fibrosis, eGFR estimated
glomerular filtration rate, MAP mean arterial pressure, U-Prot urinary
protein excretion
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morphological risk factors present. When we assessed the
study subgroups separately only according to clinical and
morphological risk factors, the decline of eGFR was the
lowest in RASb treated patients without clinical risk fac-
tors. Thus, maximal renoprotection can be achieved when
patients’ blood pressure is normal, they do not smoke and
keep their body weight within normal range. We were able
to demonstrate that RASb were only effective in prevent-
ing the progression when clinical risk factors were modest
or missing. The same question was raised by other authors
but they failed to find similar differences in the subgroups
based on treatment exposures [23].
Another aspect deserves to be pointed out. Similarly
to RASb usage also CS was prescribed to IgAN patients
who had proteinuria, more serious morphological lesions
(S1, T1/2) and lower kidney function. In our cohort the
lowest kidney function was noticed in the patients re-
ceiving CCBs or CSs. Interestingly, since KDIGO guide-
line now recommends CSs to patients with eGFR
>50 ml/min/1.73 m2, we have historically used these
drugs in many patients below a recommended level.
Coppo et al. have also reported similar findings in
VALIGA study where immunosuppression was more fre-
quently used in the patients with lower eGFR [31].
Those findings demonstrate a nephrologists’ aggressive
therapeutic attitude in treating IgAN patients with more
severe CKD and, on the other hand, leaving the patients
without severe clinical symptoms untreated.
This study also provides a novel insight into im-
portance of arteriosclerosis as well as microhematuria.
Namely, we observed arteriosclerosis being correlated
only with microhematuria in untreated patients.
Whereas this morphological lesion had no significant
correlation in the drug-treated study group and
microhematuria has generally been considered as a
benign clinical symptom, we speculate that in the
long term microhematuria may have much bigger im-
portance than expected because the decline of renal
function was still found in the untreated study group
patients. Recent findings suggest a pathogenic role for
glomerular haematuria in kidney disease [32]. Al-
though the majority of studies rule out a repercussion
of hematuria on the renal outcome of patients with
the IgAN, the true role of hematuria on renal out-
come remains uncertain [33].
We are aware of the limitations of our retrospective
study which should be considered when interpreting re-
sults. At first, our cohort was small and the treatment of
patients was not standardized. We did not have data on
the dose of RASb and in CS-received patient’ group, also
CCBs were also prescribed. Although we found the de-
cline of eGFR at the end of the follow-up, our follow-up
time may still be short considering the interpretation
and comparison of data in different study subgroups.
Conclusions
RASb are only effective in preventing the progression of
IgAN when clinical and morphological risk factors are
modest or missing. Clinical risk factors have important
influence on long-term outcome and should be managed
carefully in early stages of the disease progression. The
correlation of arteriosclerosis with microhematuria may
explain the fact that long-term microhematuria has
much bigger importance in IgAN patients than expected
because the decline of renal function was also found in
the untreated patient’ group and may be associated with
arterial damage through persistant microhematuria.
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